These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18662592)

  • 1. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.
    Sepúlveda-Vildósola AC; Betanzos-Cabrera Y; Lastiri GG; Rivera-Márquez H; Villasis-Keever MA; Del Angel VW; Díaz FC; López-Aguilar E
    Arch Med Res; 2008 Aug; 39(6):601-6. PubMed ID: 18662592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
    Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
    Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
    Navari RM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1577-86. PubMed ID: 19929251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients.
    Aapro MS; Macciocchi A; Gridelli C
    J Support Oncol; 2005; 3(5):369-74. PubMed ID: 16218261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of the use of palonosetron.
    Navari R
    Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of palonosetron: emerging data distinguishing it as a novel 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting.
    Saito M; Tsukuda M
    Expert Opin Pharmacother; 2010 Apr; 11(6):1003-14. PubMed ID: 20307224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann C; Herrstedt J
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):137-48. PubMed ID: 20131990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.
    Rzepecki P; Pielichowski W; Oborska S; Barzal J; Mlot B
    Transplant Proc; 2009 Oct; 41(8):3247-9. PubMed ID: 19857722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Mori-Vogt S; Blazer M
    Expert Rev Anticancer Ther; 2013 Aug; 13(8):919-36. PubMed ID: 23984894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the acute effect of palonosetron on transmural dispersion of myocardial repolarization.
    Dogan U; Yavas G; Tekinalp M; Yavas C; Ata OY; Ozdemir K
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):462-8. PubMed ID: 22696873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The next generation of chemotherapy-induced nausea and vomiting prevention and control: a new 5-HT3 antagonist arrives.
    Rittenberg CN
    Clin J Oncol Nurs; 2004 Jun; 8(3):307-8, 310. PubMed ID: 15208825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron (Aloxi) for prevention of nausea and vomiting due to cancer chemotherapy.
    Med Lett Drugs Ther; 2004 Mar; 46(1179):27-8. PubMed ID: 15057189
    [No Abstract]   [Full Text] [Related]  

  • 19. Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety.
    Ripaldi M; Parasole R; De Simone G; D'Amico MR; Migliorati R; Zanotta G; Loffredo G; Petruzziello F; Poggi V
    Bone Marrow Transplant; 2010 Nov; 45(11):1663-4. PubMed ID: 20173793
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives.
    Schwartzberg LS
    J Support Oncol; 2007 Feb; 5(2 Suppl 1):5-12. PubMed ID: 17366928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.